netFormulary Sunderland Joint Formulary NHS
NHS Sunderland Clinical Commissioning Group
City Hospitals Sunderland NHS Foundation Trust
 
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
08.01 Cytotoxic drugs (0,0)
Side-effects of cytotoxic drugs (0,1)
Drugs for cytotoxic-induced side-effects (5,4)
08.01.01 Alkylating drugs (11,0)
08.01.02 Anthracyclines and other cytotoxic antibiotics (10,0)
08.01.03 Antimetabolites (11,5)
08.01.04 Vinca alkaloids and etoposide (5,0)
08.01.05 Other antineoplastic drugs (21,6)
Amsacrine (1,0)
Arsenic trioxide (1,0)
Bevacizumab (1,0)
Bexarotene (0,1)
Bortezomib (1,0)
Brentuximab vedotin (1,0)
Cetuximab (1,0)
Crisantaspase (0,1)
Dacarbazine and Temozolomide (3,0)
Erlotinib (1,0)
Hydroxycarbamide (1,0)
Imatinab (0,0)
Ipilimumab (1,0)
Mitotane (1,0)
Panitumumab (0,0)
Pentostatin (0,1)
Platinum compounds (3,0)
Porfimer sodium and temoporfin (0,2)
Procarbazine (1,0)
Protein kinase inhibitors (16,2)
Taxanes (4,0)
Topoisomerase I inhibitors (2,0)
Trabectedin (1,0)
Trastuzumab (3,0)
Tretinoin (1,0)
Vismodegib (0,1)
08.02 Drugs affecting the immune response (1,0)
Immunosuppressant therapy (0,0)
08.02.01 Antiproliferative immunosuppressants (3,0)
08.02.02 Corticosteroids and other immunosuppressants (8,6)
08.02.03 Anti-lymphocyte monoclonal antibodies (4,0)
08.02.04 Other immunomodulating drugs (9,6)
Interferon Alfa (3,0)
Interferon beta (3,0)
Aldesleukin (0,1)
Glatiramer acetate (1,0)
Natalizumab (1,0)
08.03 Sex hormones and hormone antagonists in malignant disease (0,0)
08.03.01 Oestrogens (1,1)
08.03.02 Progestogens (3,0)
08.03.03 Androgens (0,0)
08.03.04 Hormone antagonists (0,0)
08.03.04.01 Breast cancer (7,1)
08.03.04.02 Prostate cancer and gonadorelin analogues (0,0)
Gonadorelin analogues (1,1)
Anti-androgens (9,0)
08.03.04.03 Somatostatin analogues (4,0)
netFormulary